Drug intelligence / Profile preview

geranylgeraniol

Development stage
Unknown
Lead developer
Ningbo Inno Pharmchem
Modality
Small Molecules
Administration
Oral
01

Overview

Geranylgeraniol (GG) is a naturally occurring 20-carbon acyclic diterpene alcohol and a key intermediate in the mevalonate pathway, primarily sourced from annatto (*Bixa orellana*). It serves as a metabolic precursor for the synthesis of geranylgeranyl pyrophosphate (GGPP), which is essential for the post-translational geranylgeranylation of small GTPases (such as Rab, Rho, and Ras), the endogenous production of coenzyme Q10 (CoQ10), and the synthesis of menaquinone-4 (Vitamin K2). Clinically, GG is being investigated for its ability to mitigate statin-associated muscle symptoms (myopathy) by bypassing HMG-CoA reductase inhibition to restore depleted GGPP levels. It is also under evaluation for its potential to support healthy testosterone levels in middle-aged adults, improve bone health by modulating osteoblast and osteoclast activity, and address metabolic disruptions in conditions like Mevalonate Kinase Deficiency (MKD) and diabetic neuropathy.

Brand names
GG-GoldGG Pure
Other names
GGOH(E,E,E)-geranylgeraniol3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-ol

Beyond the preview

Go deeper on geranylgeraniol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on geranylgeraniol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call